Physician profile
Subodh Kumar Choudhary
NPI 1700830403
$9,164.05
in general payments reported to CMS, 2019-2025
32 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 94% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $267 · 2021: $974 · 2022: $1,655 · 2023: $1,281 · 2024: $2,147 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,922 · Travel and Lodging: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,921.99 |
| Travel and Lodging | $1,647.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $1,759.47 | 2023-2024 | |
| Kerecis Limited | $1,130.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Treace Medical Concepts, INC. | $1,044.01 | 2022 | |
| Paratek Pharmaceuticals, INC. | $949.27 | 2021-2025 | Nuzyra |
| Organogenesis INC. | $882.03 | 2019-2025 | Simplimax, Affinity, Nushield |
| Stryker Corporation | $820.86 | 2019-2025 | Ortholoc 2 Lapifuse, Augment Injectable, Viaflow |
| Ani Pharmaceuticals, INC. | $398.40 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $359.40 | 2019-2023 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $329.45 | 2022-2023 | Seglentis |
| Zyla Life Sciences, INC. | $237.19 | 2019 | |
| Amgen INC. | $228.83 | 2024-2025 | Krystexxa |
| Smith+Nephew, INC. | $184.38 | 2019 | |
| Integra Lifesciences Corporation | $119.52 | 2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.00 | 2021 | |
| Medtronic, INC. | $86.05 | 2023-2025 | Intellis Adaptivestim |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $80.25 | 2022 | |
| Next Science LLC | $68.90 | 2023 | Surgx, Xperience, Blastx |
| Melinta Therapeutics, LLC | $68.10 | 2019 | |
| Nabriva Therapeutics, Plc | $44.16 | 2021-2022 | |
| Abbott Laboratories | $42.39 | 2024 | Proclaim |
| Vertex Pharmaceuticals Incorporated | $40.31 | 2025 | |
| Paragon 28, INC. | $33.42 | 2019-2022 | |
| Nevro Corp. | $25.48 | 2022 | |
| Acera Surgical, INC. | $22.39 | 2025 | Restrata Wound Matrix |
| Biowound Solutions, INC. | $22.09 | 2025 | Bio-Connekt |
| Advanced Oxygen Therapy INC. | $15.36 | 2023 | Topical Oxygen Chamber For Extremities |
| Innovation Technologies INC | $15.14 | 2025 | Irrisept |
| Sebela Pharmaceuticals INC. | $13.75 | 2023 | Naftin |
| Medela LLC | $13.09 | 2020 | |
| Zimmer Biomet Holdings, INC. | $11.76 | 2020 | |
| Hikma Pharmaceuticals USA | $11.31 | 2019 | |
| Glenmark Therapeutics INC. | $7.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subodh Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.